Sanofi announced on Oct. 12, 2017 that it is investing EUR 170 million (US$201 million) to expand a vaccine manufacturing site in Val de Reuil, France, which will include a new facility. The new facility will allow Sanofi Pasteur, Sanofi s global vaccines business unit, to expand supply of VaxigOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.